A single dose of a pharmaceutical formulation of LSD cut anxiety scores by about 5 points more than placebo over 12 weeks, according to topline results from the Panorama study released Monday by Definium Therapeutics.
Panorama enrolled 245 adults with generalized anxiety disorder across about 32 centers. On the Hamilton Anxiety Rating Scale at week 12, the 100 microgram group improved by 9.8 points from baseline against 4.7 on placebo, a difference of 5.1 points with a p-value below 0.0001 and a standardized effect size of 0.64.
The drug, DT120, is an orally disintegrating tablet containing lysergide, the tartrate salt of LSD. Readers following this program earlier will know it as MM120, developed by MindMed. The company now trades as Definium Therapeutics, and Panorama is still registered under the identifier MM120-301. The compound is a Schedule I controlled substance. It is not approved for any use and cannot be legally prescribed or purchased anywhere in the United States.
That distinction matters most for anyone struggling with anxiety. What was tested is a measured dose given once, in a clinic, under at least eight hours of supervision. It bears no resemblance to obtaining LSD outside medical care.
A Five Point Difference on a Scale That Started Near Twenty Eight
Participants entered with mean anxiety scores of 28.3 in the 100 microgram group and 28.0 on placebo, which places them in the severe range on a scale where scores above 24 typically indicate severe symptoms. Both groups improved. The treated group improved roughly twice as much.
All three multiplicity-controlled secondary endpoints were met. Clinician-rated illness severity improved by 1.0 point against 0.5 on placebo at week 12, and by 1.1 against 0.3 as early as day 2. Anxiety scores at week 1 showed a 5.3-point separation from placebo, and the company said the effect held at every measured time point during the blinded period.
Panorama follows earlier Phase 3 results in anxiety from the Voyage trial, reported in August, and the Emerge trial in major depressive disorder, reported in June. This is the company's third positive Phase 3 readout and its second in anxiety, which is the kind of replication regulators generally want before an approval. The compound holds FDA Breakthrough Therapy designation for both generalized anxiety disorder and major depression.
A Third Responded, Which Leaves Two Thirds Who Did Not
Average scores flatter a drug. Response rates tell patients more.
At week 12, 32 percent of the treated group met the standard response threshold of at least 50 percent symptom reduction, against 14 percent on placebo. Remission, defined as a score of 7 or below, reached 15 percent against 4 percent. About 35 percent ended with mild or better symptoms, against 17 percent on placebo.
Those are meaningful margins in a condition where little has changed for two decades. They also mean most participants did not respond, and only about one in seven reached remission. A single dose is not a cure for a chronic condition. The trial's own design allows up to four additional doses during a 40-week open-label extension, based on symptom severity.
Blinding is the other honest limitation. A psychedelic is difficult to disguise, and participants can often tell which group they are in, which can inflate apparent benefit. The company included a lower dose arm to limit unblinding, and that 50 microgram group, which had 52 participants and was not powered for statistical comparison, showed a smaller effect consistent with a dose-response pattern. Side-effect rates still differed sharply between the 100 microgram and placebo groups, at 94.8 percent and 62.9 percent.
Eight Hours of Monitoring Is Part of the Treatment
That high overall rate needs context. Adverse events were collected under FDA guidance for psychedelic drug development, which counts expected effects of the drug even when they are neutral or positive. The most common effects on dosing day in the 100 microgram group were illusion, meaning altered perception, at 68 percent, nausea at 37 percent, and headache at 24 percent. The company said most events were mild to moderate, transient, and confined to the dosing day, with no drug-related serious adverse events, no new safety signals, and no suicidality signal. Discontinuation rates were similar across all three arms, at 10.4 percent, 11.5 percent, and 10.3 percent.
Participants were monitored for a minimum of eight hours and assessed hourly starting five hours after dosing against a structured end-of-session checklist. The average time to meet those criteria was 6.2 hours, with a median of 6.0, and 94 percent of participants cleared them by hour 8. Across more than 1,000 dosing sessions in the Phase 3 program, the company's full topline disclosure puts that figure at 97 percent.
That supervision requirement shapes what access would look like if the drug is ever approved. This is not a prescription someone fills and takes at home. It implies a clinic, a trained monitor, and most of a working day, which raises real questions about capacity, staffing, and who can afford the time off.
Scott Aaronson, chief science officer at the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt and a Panorama investigator, said the notable feature is that "a single dose has the potential to hold a response for months"without daily pill-taking, removing the adherence burden and side effects that come with existing daily medications.
Scheduling, Access and the Road to a 2027 Filing
Definium says it has a pre-application meeting with the FDA scheduled for the fourth quarter of 2026 and plans to file in the first half of 2027. Even a smooth review would put a decision well beyond that. Separately, the Drug Enforcement Administration would need to reschedule the compound before it could be legally marketed, a step the company flags in its own risk disclosures.
How many Americans this could serve is itself contested. Definium cites roughly 26 million US adults with generalized anxiety disorder, drawing on a 2023 national prevalence study, census data, and internal estimates. The National Institute of Mental Health reports a past-year prevalence of 2.7 percent based on older survey data, which corresponds to a considerably smaller figure. Both numbers are sourced. They rest on different surveys and different years, and the gap has not been resolved.
What is not in dispute is that options have been static. The last new drug approval for generalized anxiety disorder came in 2007.
Anyone struggling with anxiety has effective, available options today, including therapy and approved medications, and a primary care clinician or licensed mental health professional is the right starting point. Nobody should stop a prescribed medication based on trial results for an unapproved drug. This is a sensitive subject, and if anxiety or low mood is affecting daily life, support is available, and a clinician can help sort through which treatments fit.
Key Questions Answered
What did the trial find? A single 100 microgram dose of DT120 reduced anxiety scores by 5.1 points more than placebo at week 12, and met all three multiplicity-controlled secondary endpoints.
What exactly is DT120? An orally disintegrating tablet containing lysergide, a pharmaceutical formulation of LSD, developed earlier as MM120. It is a Schedule I controlled substance and is not approved for any medical use.
Is this available to patients? No. It can only be received through a clinical trial. It cannot be legally prescribed or purchased.
How many patients actually improved? About 32 percent met the response threshold against 14 percent on placebo, and 15 percent reached remission, compared with 4 percent. Most participants did not respond.
What were the side effects? Altered perception in 68 percent of the 100 microgram group, nausea in 37 percent and headache in 24 percent, mostly mild to moderate and limited to dosing day. No drug-related serious adverse events were reported.
Why does supervision matter? Participants were monitored for at least eight hours, taking an average of 6.2 hours to meet discharge criteria. Any approved version would require clinic time, not home dosing.
When could a decision come? The company plans a pre-application FDA meeting in late 2026 and a filing in the first half of 2027. Rescheduling by the DEA would also be required before marketing.
